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A b s t r a c t  
The aim of this study was to determine the effects of β-lactoglobulin (β-LG) on the intestinal 
absorption of cyclosporin A (CsA) in vivo and in vitro. After intraduodenal co-administration of CsA (5 
mg/kg) with 150 mg/kg β-LG, Tmax was significantly lower than that of control rats which were given 
the same dose of CsA without β-LG. Cmax and AUC were significantly increased as compared with 
the control while T1/2 were not significant. Moreover, a deconvolution method revealed that the rate 
of CsA absorption was enhanced by β-LG (150 mg/kg) by about 12 times. These results indicate 
that β-LG significantly enhanced the rate of CsA absorption and the extent of CsA bioavailability in 
the gut. β-LG did not change the solubility of CsA in vitro, but β-LG increased the apical-to-
basolateral permeability clearance of CsA (PScell), with pronounced increase in the permeability of 
unbound CsA (PSu,cell), across the Caco-2 monolayers in a concentration-dependent manner in 
vitro.  It was thus considered that β-LG-mediated transport of CsA might be a possible mechanism to 
enhance the intestinal absorption of CsA in vivo. 
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Introduction 
β-Lactoglobulin (β-LG) is a major whey protein of bovine milk, and 
has been reported to help absorption of lipophilic vitamins in 
neonates whose bile acids secretion is not matured. [1] β-LG 
shows a resistance to acidic pH therefore it has been introduced as 
a carrier to increase the stability for several compounds and 
nutrients.[2,3]  However, the effect of β-LG on the gastrointestinal 
absorption of lipophilic drugs has not been examined quantitatively 
so far.  Cyclosporine (CsA) is an immunosuppressive drug, and its 
oral bioavailability is low due to its poor absorption which is related 
to water insolubility, P-glycoprotein (P-gp)-mediated efflux, and 
first-pass metabolism by CYP3A4 in the liver and gut.[4] Some 
strategies have been proposed to enhance the absorption of CsA 
by using absorption enhancers including surfactants, fatty acids, or 
chitosan derivatives to modify cell membrane permeability or 
modulate gut tight junctions.[5] However, local toxicities of these 
absorption enhancers on intestinal epithelial cells are the matter of 
concern, and the development of a safer and effective absorption 
enhancer for CsA has thus been paid much attention. The aim of 
this study, therefore, was to determine the effect of -LG on the 
intestinal absorption of CsA in vivo and estimate the rate of 
absorption by a deconvolution method. Moreover, the effects of -
LG on the solubility of CsA and the permeability of CsA across the 
Caco-2 monolayer model were determined in vitro. 
 
Materials and Methods 
 
Animals   Male Wistar rats weighing from 250 to 280 g were 
provided by Nihon Ikagaku Doubutsu, Saitama, Japan. The rats 
were housed under standard food and water ad libitum and 
acclimatized to environmental control (a temperature-controlled 
facility with a 12-h light/dark cycle) for at least one week before 
use. All the animal experiments were conducted according to the 
guidelines for Animal Experimentation in Showa University.  
Reagents    -LG was purchased from Sigma-Aldrich (St. Louis, 
MO, USA), and Caco-2 cells from American type culture collection 
(Manassas, VA, USA). CsA was supplied by Novartis (Tokyo, 
Japan), and [mebmt-β-3H]-cyclosporin A ([3H]-CsA) from 
Amersham Life Science (Buckinghamshire, England).  All other 
reagents used were commercially available and of analytical grade. 
 
Effect of -LG on intestinal absorption of CsA   
 
The rats were fasted for approximately 12 h with water given ad 
libitum and then anesthetized by pentobarbital (40 mg/kg). The 
femoral artery was cannulated with polyethylene tubing (SP-31, 
Natsume Seisakusho, Tokyo, Japan) filled with saline and EDTA to 
facilitate blood sampling. In order to exclude the variability in effect 
as a result of gastric emptying, -LG was administered 
intraduodenally to rats. Polyethylene micro-tubing (PE50) was used 
for duodenal cannulation according to the method previously 
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reported.[6]  The abdominal cavity of the femoral artery-cannulated 
rats was opened and the distal part of the duodenum was exposed 
and clamped gently. The clamped duodenum was punctured using 
an 18-gauge needle and a cannula was inserted at the punctured 
site of the duodenum and the purse sutures were tightened around 
the cannula. The clamp was removed, and the cannula was flushed 
by physiological saline. The cannulated rat was kept for 18-24 hr in 
a Bolman cage and the experiment was performed following 
recovery from anesthesia. 
CsA was dissolved in corn oil and given intraduodenally at the dose 
of 5 mg/kg (4.16 µmol/kg) alone (i.e. control group) or together with 
-LG 15 mg/kg (0.81 µmol/kg) or 150 mg/kg (8.13 µmol/kg).  At 
0.08, 0.25, 0.5, 1, 2, 4, 8, and 12 hr after administration of CsA, 
blood samples (120µl) were taken into plastic tubes containing 
EDTA and stored at 4C until assay. CsA concentrations in whole 
blood samples were assayed by high-performance liquid 
chromatography (HPLC), as described later.  
 
Pharmacokinetic Analysis 
 
Pharmacokinetic parameters of CsA, i.e., the area under the 
concentration-time curve from 0 to infinity (AUC0-), elimination 
half-life (T1/2), mean residence time (MRT), the maximum blood 
concentration (Cmax), volume of distribution (Vdss/F), total body 
clearance (CLtot/F), and time to reach Cmax (Tmax), were 
calculated by a non-compartmental analysis using WinNonlinTM 
(version 4.0.1, Pharsight Corporation, Mountain Veiw, CA ,USA).  
The intestinal absorption rate of CsA after intraduodenal 
administration to rats was calculated by a deconvolution method. 
Blood concentration of CsA after oral CsA administration as a 
function of time, Cpo(t), is expressed as follows[7]: 
  
     dtCftC
t
ivpo  
0
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   (1) 
where f(t) and Civ(t) are the absorption rate and the blood 
concentration, respectively,  at time t after intravenous injection of 
CsA. When the amount of f() is rapidly injected to the systemic 
circulation at time , blood concentration associated with the pulse 
is f()Civ(t-) at time t.  Equation 1 holds since an absorption 
rate-time profile is composed of an infinite number of the input 
pulses. Absorption profiles of CsA were estimated by deconvoluting 
Cpo(t) with Civ(t) in Eq. 1.[8] Civ(t) used in this analysis was cited 
from a previous study[9], where the same dose of CsA (5mg/kg) 
was intravenously administered to rats. 
 
Effects of -LG on the solubility of CsA  
 
The solubility of CsA was determined according to a method 
described by Jiko et al. [10] with some modifications. Briefly, CsA 
(10 mg) was added to 0.5% sodium carboxymethyl cellulose (CMC-
Na) solution (5 ml) in the absence or presence of -LG (30 mg). 
Samples were centrifuged at 15,000 x g for 20 min. Then, aliquots 
of supernatant were taken, diluted with saline and filtrated through 
a microfilter (pore size 0.45µm) before CsA was quantified by 
HPLC. 
 
Effect of -LG on permeability of CsA across the Caco-
2 monolayer model  
 
Caco-2 cells, seeded at a density of 6 x 104 cells/cm2 on the 
Transwell® permeable polycarbonate filters (12 mm diameter, 0.4 
mm pore size, 1 cm2 growth area) (Coring Costar Corp., 
Cambridge, MA, USA) were cultured as previously described. [10]  
The Caco-2 monolayer cultured on a polycarbonate filter was then 
mounted into the diffusion apparatus (Coring Costar Corp.).  The 
cells and PC membrane faced the donor and receiver chambers 
nominated as the apical (A) and basolateral (B) sides, respectively. 
Then, 5 ml of HBSS was pipetted into the A and B sides of the 
diffusion cells maintained at 37°C, where 95%O2/5%CO2 was 
bubbled continuously. Transport study was initiated by adding [3H]-
CsA (0.5µCi/ml) at various concentrations of -LG (0, 0.2, 1, 2 and 
20 µM) into the A side of the diffusion cells. Aliquots of 100 l of 
the incubation mixture were taken from the B chamber at 0, 30, 60, 
90, and 120 min and the radioactivity measured by a liquid 
scintillation counting (LSC-5200, Aloka, Japan).  
The amount of [3H]-CsA (Cr) transported to the receiver side (i.e., 
the B side) was plotted against time t (min), and the apparent 
permeability clearance of [3H]-CsA across the cells cultured on a 
PC filter (PStotal) was calculated according to a previous report 
[11] as follows: 
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where dCr/dt represents the transport rate of [3H]-CsA, calculated 
by plotting the amount of [3H]-CsA transported against time and 
determining the slope of the regression line (µCi/ml/min), V is the 
volume in the receiver chamber (µl) and C0 represents the initial 
concentration of [3H]-CsA in the donor chamber (µCi/ml). 
In another study, Cr in the absence of the cells (i.e., filter only) at 
various concentrations of -LG (0, 0.2, 1, and 20 µM) were also 
plotted against time t (min), and the permeability clearance of [3H]-
CsA across the filter without cells (PSfilter) was calculated by Eq. 
(2). 
 The transcellular permeability clearance of [3H]-CsA across the 
Caco-2 cells (PScell) was calculated as follows[11]:  
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The unbound [3H]-CsA in the donor-side medium (fu) was 
determined as follows: 
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where PSfilter(+  -LG) and PSfilter(-  -LG)  represent the 
permeability clearances of [3H]-CsA across the filter (without 
Caco2-cells) in the presence and absence of   -LG, respectively.
The intrinsic permeability clearance of unbound [3H]
the Caco-2 cells (PSu,cell) was calculated by Eq.5 as follows:
 u
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f
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HPLC Analysis    
  
CsA concentrations in whole blood samples were assayed by a 
high-performance liquid chromatographic (HPLC) system, as 
previously described[12] with minor modifications. Briefly, aliquots 
of 100  l of whole blood were dispensed in 10 ml glass tubes. The 
tube was vortexed and 4 ml of diethyl ether was added into tube for 
drug extraction. The extracts were centrifuged at 3,000 rpm for 5 
min. Supernatants was transferred and evaporated using a gentle 
stream of air. The extract residues were reconstituted using 
acetonitrile and 0.04 M monobasic potassium phosphate (pH 2.5) 
(65:35 v/v) and washed twice with 3 ml of n-hexane. Sample (70 µl) 
 
Figure. 1 The blood concentration-time profiles of CsA in rats after intraduodenal administration of CsA with or without 
*, ** represent p<0.05 and 
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1 ml of 
was injected into the HPLC system composed of a dual pump (DP
8020, Tosoh, Tokyo, Japan), a UV detector (UV
column oven (CO-8000, Tosoh), a degasser (SD 8022, Tosoh), and 
a digital recorder (Chromatocorder 21, Tosoh).  The reversed
phase column used was a Cadenza CD
(Imtakt Co., Kyoto, Japan) equipped with a Nova
column, (Waters Corp., Milford, MA, USA). The mobile phase was 
a mixture of acetonitrile–0.04 M monobasic potassium phosphate 
(pH 2.5) (65:35 v/v) and pumped at a flow rate of 1 ml/min. 
Detection was set at wavelength of 205 nm. The calibration curves 
were prepared each time in a concentration range from 0.1
µg/ml. The correlation coefficients (linearity) were consistently more 
than 0.95.  
 
Statistical Analysis 
   
 Data were expressed as the mean 
Comparisons between two groups and among more than three 
groups were performed using Student’s t
for multiple comparisons among the groups, followed by Dunnett’s 
post hoc test for the individual difference
was considered to be statistically significant if the probability value 
was less than 0.05 (p<0.05).  
 
Results and Discussion 
 
β-LG is a lipocalin protein family which has a 
parallel β-strands with a hydrophobic interior. 
ability to bind a variety of compounds including 
phospholipids, phenolic compounds, fatty acids, 
hydrophobic molecules  via tight binding inside its hydrophobic 
calyx. [1]  
Each value is expressed as the mean  S.D. (n=6). 
p<0.01, respectively as compared with the control group (without 
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Certain compositions of milk such as milk fat globule membranes 
(MFGM) have been reported to enhance the intestinal absorption of 
lipophilic drugs including CsA after administered concomitantly. [13] 
In accordance, our in vivo data show that -LG increased blood 
concentration of CsA in concentration dependent manner (Fig. 1). 
Co-administration of 150 mg/kg -LG significantly increased AUC 
and Cmax of CsA by about 30% and 100%, respectively, as 
compared with control (p<0.05) (Table 1). Tmax after co-
administration of CsA with 15 and 150 mg/kg -LG was 
significantly lower than that of control (p<0.05). Moreover, we 
calculated the intestinal absorption rate by using a deconvolution 
method using the profiles of the CsA concentrations in blood after 
intravenous and intraduodenal administrations. As a result, the 
average rates of CsA absorption were determined to be 9.3 % 
dose/hr with 15 mg/kg -LG, 24 % dose/hr with 150 mg/kg -LG, 
and 1.9 % dose/hr with the control.  Therefore, the rates of CsA 
absorption in the presence of 15 and 150 mg/kg -LG were greater 
than that of control by about 4 and 12 times, respectively. In 
contrast, T1/2 was not significantly different among the -LG and 
control groups, indicating that the hepatic clearance of CsA did not 
change. These results clearly indicate that -LG enhances the rate 
and extent of the gastrointestinal CsA absorption. 
 
                                                    Table 1 : Pharmacokinetic parameters of CsA after intraduodenal administration in rats  
 
Parameters (unit) Control 
(5mg/kg CsA) 
Co-administration 
with 15 mg/kg -
LG 
Co-administration with 150 
mg/kg -LG 
T1/2 (hr)   3.201.20 3.20 0.49 2.55  0.25 
Cmax (ng/ml)   379  208 604  79 763  140* 
Tmax (hr)    4.0  0.0 1.50 0.58* 0.50  0.0* 
AUC(ng/mlhr) 1753  214 2097  310 2297 247* 
CLtot/F (L/hr/kg) 3.56  1.94 2.43  0.37 2.25  0.49* 
Vd/F (L/kg) 19.1  9.60 8.97  1.47 7.39  1.0* 
MRT (hr) 5.86  0.38 3.71 0.44* 3.35  0.50* 
Each value is expressed as the mean  S.D. (n=6).  * p<0.05 as compared with the control group (without -LG). 
 
Very low solubility of CsA in aqueous solution is considered to limit 
the oral bioavailability of CsA. -LG has been reported to bind and 
solubilize several compounds, such as resveratrol, theophylline and 
sulfamethoxazole. [14,15] We preliminarily expected that β-LG 
binds CsA and thus may increase the drug solubility. However, we 
found that -LG did not actually affect the solubility of CsA, as 
compared with control (63.2 ± 0.31 vs 67.7 ± 11.2 µg/ml in the 
absence and presence of -LG, respectively).  
 
                Table 2 : The permeability clearances of [3H]-CsA without and with -LG (0.2, 1 and 20 M) in Caco-2 cell monolayer model  
 
Group PSfilter 
(µl/min) 
 
PScell 
(µl/min) 
fu PSu,cell 
(µl/min) 
(%of control) 
Without β-LG 156.3±19.2 3.80± 1.12 1 3.8 (100%) 
0.2µM β-LG 108.2± 10.3 3.45± 0.68 0.69 5.0 (131%) 
1 µM β -LG 59.2± 6.4 4.25± 1.02 0.55 7.8 (204%) 
20 µM β-LG 15.9± 2.1 7.15± 0.67 0.38 18.5 (486%) 
 
Each value of PSfilter and PScell is expressed as the mean  S.D. of 3-4 experiments. 
 
fu and PSu,cell represent the fraction unbound and the intrinsic 
permeability clearance of unbound [3H]-CsA, respectively, 
calculated as the mean values by Eq. 4 and 5. 
 As shown in Table 2, PSfilter and PScell of [3H]-CsA were calculated 
to be 156.3 ±19.2 and 3.80 ± 1.12 µl/min in the absence of -LG, 
respectively, indicating that the cell permeability is the rate-limiting 
barrier of overall [3H]-CsA transport across the Caco-2 monolayer 
cultured on a polycarbonate filter. PSfilter of [3H]-CsA was 
extensively decreased in the presence of -LG in a concentration-
dependent manner,  indicating that the binding of [3H]-CsA with -
LG resulted in the reduction of unbound fraction of [3H]-CsA in the 
donor chamber. In contrast, PScell of [3H]-CsA was significantly 
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increased in the presence of -LG in a concentration-dependent 
manner, indicating that the binding of [3H]-CsA with -LG 
enhanced the transcellular transport of [3H]-CsA across the Caco-2 
cells. It was also shown that -LG increased the apical-to-
basolateral intrinsic permeability clearance of unbound CsA 
(PSu,cell). Therefore, it was suggested that β-LG binding with CsA 
may contribute to the accelerated transport of the drug across the 
Caco-2 cells, probably by efficiently carrying lipophilic CsA 
molecules across the unstirred water-layer adjacent to the apical 
side of Caco-2 cells and by rapidly dissociating CsA molecules at 
the proximity of Caco-2 cell membranes (generally referred to as 
protein-mediated transport).  Thus, β-LG may act as a carrier-
protein of CsA, in consistent with a previous report that β-LG 
enhanced the intestinal absorption of palmitate[16], retinol [17], and 
fatty acid [17]. Another example of protein-mediated transport can 
be seen with fatty acids, as Burczynski et al.[18] reported that the 
uptake of [3H]-palmitate by hepatocytes was statistically greater in 
the presence of chemically modified albumin which has higher pI 
values, and therefore concluded that the protein-mediated complex 
does interact with hepatocyte membrane. Moreover, Yi et 
al.[19]recently demonstrated that  -carotene-encapsulated β-
lactoglobulin–dextran-conjugated nanoparticles are stable under 
gastric pH conditions and can release  -carotene with high 
permeability to Caco-2 cells; thus, β-LG was suggested to be a 
good carrier for oral delivery of the very lipophilic vitamin A 
precursor.  
Taken altogether, the present study suggested that β-LG-mediated 
transport of CsA is a possible mechanism to explain the enhancing 
effect of -LG on the intestinal absorption of CsA in vivo. 
 
Conclusion 
 
 In summary, we provided in vivo and in vitro evidence to show that 
 -LG increases the rate and extent of gastrointestinal absorption of 
CsA, suggesting that  -LG could be used as an oral absorption 
enhancer for lipophilic drugs.   
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